SI0885212T1 - Quinoxalinediones - Google Patents

Quinoxalinediones

Info

Publication number
SI0885212T1
SI0885212T1 SI9730225T SI9730225T SI0885212T1 SI 0885212 T1 SI0885212 T1 SI 0885212T1 SI 9730225 T SI9730225 T SI 9730225T SI 9730225 T SI9730225 T SI 9730225T SI 0885212 T1 SI0885212 T1 SI 0885212T1
Authority
SI
Slovenia
Prior art keywords
quinoxalinediones
Prior art date
Application number
SI9730225T
Other languages
English (en)
Slovenian (sl)
Inventor
David John Bull
Christopher Lee Carr
Michael Jonathan Fray
Elisabeth Colette Louise Gautier
Charles Eric Mowbray
Alan Stobie
Original Assignee
Pfizer Research And Development Company, N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.
Publication of SI0885212T1 publication Critical patent/SI0885212T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
SI9730225T 1996-03-09 1997-02-27 Quinoxalinediones SI0885212T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9605027.3A GB9605027D0 (en) 1996-03-09 1996-03-09 Quinoxalinediones
EP97908156A EP0885212B1 (en) 1996-03-09 1997-02-27 Quinoxalinediones
PCT/EP1997/000995 WO1997032873A1 (en) 1996-03-09 1997-02-27 Quinoxalinediones

Publications (1)

Publication Number Publication Date
SI0885212T1 true SI0885212T1 (en) 2002-02-28

Family

ID=10790134

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730225T SI0885212T1 (en) 1996-03-09 1997-02-27 Quinoxalinediones

Country Status (42)

Country Link
US (1) US6376490B1 (no)
EP (1) EP0885212B1 (no)
JP (1) JP3110467B2 (no)
KR (1) KR100288099B1 (no)
CN (1) CN1103770C (no)
AP (1) AP767A (no)
AR (1) AR006119A1 (no)
AT (1) ATE208773T1 (no)
AU (1) AU717972B2 (no)
BG (1) BG63340B1 (no)
BR (1) BR9707851A (no)
CA (1) CA2248366C (no)
CO (1) CO4770976A1 (no)
CZ (1) CZ292792B6 (no)
DE (1) DE69708269T2 (no)
DK (1) DK0885212T3 (no)
DZ (1) DZ2188A1 (no)
EA (1) EA001730B1 (no)
ES (1) ES2163742T3 (no)
GB (1) GB9605027D0 (no)
HN (1) HN1998000034A (no)
HR (1) HRP970132A2 (no)
HU (1) HUP9900975A3 (no)
ID (1) ID18112A (no)
IL (1) IL125491A (no)
IS (1) IS4811A (no)
MA (1) MA26422A1 (no)
NO (1) NO984058L (no)
NZ (1) NZ331060A (no)
OA (1) OA10850A (no)
PE (2) PE43398A1 (no)
PL (1) PL329032A1 (no)
PT (1) PT885212E (no)
SI (1) SI0885212T1 (no)
SK (1) SK283467B6 (no)
TN (1) TNSN97044A1 (no)
TR (1) TR199801782T2 (no)
TW (1) TW454004B (no)
UY (1) UY24482A1 (no)
WO (1) WO1997032873A1 (no)
YU (2) YU39698A (no)
ZA (1) ZA971987B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ336842A (en) * 1997-02-27 2000-05-26 Pfizer Process of making quinoxalinediones to produce antagonistic effect at NMDA receptors
AP982A (en) * 1997-02-27 2001-07-16 Pfizer Quinoxalinediones.
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
DE10005150A1 (de) * 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
CA2409819C (en) * 2000-05-19 2009-09-15 Yamanouchi Pharmaceutical Co., Ltd. Triazole derivatives
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
MY145368A (en) 2004-01-13 2012-01-31 Nissan Chemical Ind Ltd Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
US7799894B2 (en) 2004-02-06 2010-09-21 Yamaguchi University Electrode for energy storage device and process for producing the same
JP2007223901A (ja) * 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
US20060211739A1 (en) * 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
CA2686816A1 (en) 2007-01-16 2008-07-24 The Johns Hopkins University Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CN101679383B (zh) * 2007-05-17 2014-10-29 株式会社半导体能源研究所 三唑衍生物,和使用三唑衍生物的发光元件、发光器件和电子器件
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US9879004B2 (en) * 2013-02-07 2018-01-30 Merck Patent Gmbh Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN111548320B (zh) * 2019-10-09 2023-03-24 贵州大学 一类1,3,4-噁二唑酰肼类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132340T2 (de) * 1990-11-06 2001-02-08 Yamanouchi Pharmaceutical Co., Ltd. Kondensiertes pyrazinderivat
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
NZ336842A (en) * 1997-02-27 2000-05-26 Pfizer Process of making quinoxalinediones to produce antagonistic effect at NMDA receptors

Also Published As

Publication number Publication date
TNSN97044A1 (fr) 2005-03-15
AR006119A1 (es) 1999-08-11
PL329032A1 (en) 1999-03-01
PE58199A1 (es) 1999-06-11
AU717972B2 (en) 2000-04-06
US6376490B1 (en) 2002-04-23
SK283467B6 (sk) 2003-08-05
NO984058D0 (no) 1998-09-03
AP767A (en) 1999-09-29
GB9605027D0 (en) 1996-05-08
EA199800702A1 (ru) 1999-04-29
KR19990087614A (ko) 1999-12-27
ES2163742T3 (es) 2002-02-01
CN1103770C (zh) 2003-03-26
MA26422A1 (fr) 2004-12-20
DE69708269T2 (de) 2002-07-25
IL125491A0 (en) 1999-03-12
EA001730B1 (ru) 2001-08-27
ATE208773T1 (de) 2001-11-15
JPH11506123A (ja) 1999-06-02
CZ292792B6 (cs) 2003-12-17
UY24482A1 (es) 2000-09-29
TR199801782T2 (xx) 1998-12-21
DK0885212T3 (da) 2002-03-25
ID18112A (id) 1998-03-05
KR100288099B1 (ko) 2001-05-02
CA2248366C (en) 2002-06-04
CA2248366A1 (en) 1997-09-12
SK121498A3 (en) 2000-10-09
BG102760A (en) 1999-09-30
JP3110467B2 (ja) 2000-11-20
BR9707851A (pt) 1999-07-27
CZ286498A3 (cs) 1999-07-14
NO984058L (no) 1998-11-06
OA10850A (en) 2001-08-16
YU41199A (sh) 2001-09-28
HUP9900975A3 (en) 2001-12-28
WO1997032873A1 (en) 1997-09-12
HN1998000034A (es) 1999-02-09
CO4770976A1 (es) 1999-04-30
EP0885212A1 (en) 1998-12-23
PT885212E (pt) 2002-02-28
YU39698A (sh) 1999-03-04
IS4811A (is) 1998-07-27
DE69708269D1 (de) 2001-12-20
AP9700947A0 (en) 1997-04-30
AU2023197A (en) 1997-09-22
TW454004B (en) 2001-09-11
BG63340B1 (bg) 2001-10-31
ZA971987B (en) 1998-09-07
HRP970132A2 (en) 1998-06-30
IL125491A (en) 2003-07-06
HUP9900975A2 (hu) 1999-07-28
EP0885212B1 (en) 2001-11-14
CN1213369A (zh) 1999-04-07
NZ331060A (en) 2000-01-28
PE43398A1 (es) 1998-08-29
DZ2188A1 (fr) 2002-12-02

Similar Documents

Publication Publication Date Title
DE59704951D1 (en) Plättchenförmiges titandioxidpigment
DE69711882D1 (en) Carbolinderivate
GB9605027D0 (en) Quinoxalinediones
DE59705192D1 (en) Lcp-blends
PL331557A1 (en) Arylakanoyl pyridiazines
DE59700372D1 (en) Blockcopolymere
DE69621466D1 (en) Thermoplastische hydroxy-phenoxyetherpolymerverbundwerkstoffe
DE59707730D1 (en) Peripheralpumpe
DE59704086D1 (en) Twin-dualmode-filter
DE59703905D1 (en) Linearmotorgetriebene transportanlage
GB9618169D0 (en) Sedimenter
DE59702027D1 (en) Bragg-modulator
DE59703023D1 (en) Cyclopeptidderivate
DE59711583D1 (en) Heterocyclyluracile
DE59709914D1 (en) Substituierte aromatische phosphonsäurederivate
IL131120A0 (en) Quinoxalinediones
DE59705556D1 (en) Peripheralpumpe
HUP9901287A3 (en) Coin-checking arrangement
AU131132S (en) Handleset
AU131198S (en) Handleset
DE59610178D1 (en) Rotationspumpe
AU131131S (en) Handleset
GB9622084D0 (en) Transinduction
GB9621514D0 (en) Vamper
AU131199S (en) Handleset